stockrowDENTSPLY SIRONA Inc.
XRAY Healthcare Medical Instruments & Supplies
DENTSPLY SIRONA Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, down 2.98% from fiscal 2024.
- Revenue
- −7.52%
- EPS
- +99.5%
- Free cash flow
- −18.0%
- Total debt
- −1.59%
Quarter to September 2026, against a year earlier
Follow XRAY
Alert me
DENTSPLY SIRONA Inc. (XRAY) EBITDA
DENTSPLY SIRONA Inc.'s EBITDA for fiscal 2025 was $455.0M, up 87.2% from $243.0M in fiscal 2024. Over the twelve months to 30 June 2026 it was $408.0M. Over the past ten years it has ranged from $243.0M (fiscal 2024) to $954.0M (fiscal 2021); the current reading is higher than 27% of that period. DENTSPLY SIRONA Inc. ranks 15th of 47 Medical Instruments & Supplies companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $455.0M | 87.24% |
| FY2024 | $243.0M | (55.74%) |
| FY2023 | $549.0M | (5.02%) |
| FY2022 | $578.0M | (39.41%) |
| FY2021 | $954.0M | 95.49% |
| FY2020 | $488.0M | (27.81%) |
| FY2019 | $676.0M | 46.32% |
| FY2018 | $462.0M | 13.35% |
| FY2017 | $407.6M | (44.23%) |
| FY2016 | $730.9M | 43.48% |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $167.0M | 279.55% |
| Mar 2026 | $44.0M | (37.14%) |
| Dec 2025 | $70.0M | (44.88%) |
| Sep 2025 | $127.0M | 9.48% |
| 42 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| XRAY DENTSPLY SIRONA Inc. | $408.0M |
| STVN Stevanato Group S.p.A. compare | $351.1M |
| LMAT LeMaitre Vascular, Inc. compare | $88.7M |
| WRBY Warby Parker Inc. compare | $59.0M |
| ATRC AtriCure, Inc. compare | $34.2M |
| AZTA Azenta, Inc. compare | $28.1M |
| STAA STAAR Surgical Company compare | $23.2M |
| PLSE Pulse Biosciences, Inc compare | −$82.0M |
| KMTS Kestra Medical Technologies, Ltd. compare | −$133.4M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on XRAY
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement